Targeting the WNT/β-catenin/TCF/LEF1 axis in solid and haematological cancers: Multiplicity of therapeutic options

European Journal of Cancer

Volumn 45, Issue 16, 2009, Pages 2759-2767

  Gehrke, Iris ^a   Gandhirajan, Rajesh Kumar ^a   Kreuzer, Karl Anton ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Catenin; Drug target; Lymphoid enhancer factor 1 (LEF1); T cell factor (TCF); WNT signalling

Indexed keywords

BETA CATENIN; LYMPHOID ENHANCER FACTOR 1; T CELL FACTOR PROTEIN; WNT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; GENE EXPRESSION; GENE TARGETING; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL; HUMAN; LYMPHOBLASTOMA; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; T CELL LEUKEMIA;

ANIMALS; BETA CATENIN; DOWN-REGULATION; HEMATOLOGIC NEOPLASMS; HUMANS; LYMPHOID ENHANCER-BINDING FACTOR 1; MICE; MUTATION; NEOPLASMS; SIGNAL TRANSDUCTION; T CELL TRANSCRIPTION FACTOR 1; WNT PROTEINS;

EID: 70350023790     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.08.003     Document Type: Article

References (66)

1. Moon R.T., Brown J.D., and Torres M. WNTs modulate cell fate and behavior during vertebrate development. Trends Genet 13 (1997) 157-162
2. Cadigan K.M., and Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 11 (1997) 3286-3305
3. Dickinson M.E., and McMahon A.P. The role of Wnt genes in vertebrate development. Curr Opin Genet Dev 2 (1992) 562-566
4. Polakis P. Wnt signaling and cancer. Genes Dev 14 (2000) 1837-1851
5. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., and Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378 (1995) 785-789
6. Lu Z., and Hunter T. Wnt-independent beta-catenin transactivation in tumor development. Cell Cycle 3 (2004) 571-573
7. Niemann S., Zhao C., Pascu F., et al. Homozygous WNT3 mutation causes tetra-amelia in a large consanguineous family. Am J Hum Genet 74 (2004) 558-563
8. Reya T., O'Riordan M., Okamura R., et al. Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity 13 (2000) 15-24
9. Austin T.W., Solar G.P., Ziegler F.C., Liem L., and Matthews W. A role for the Wnt gene family in hematopoiesis: expansion of multilineage progenitor cells. Blood 89 (1997) 3624-3635
10. Van Den Berg D.J., Sharma A.K., Bruno E., and Hoffmann R. Role of members of the Wnt gene family in human hematopoiesis. Blood 92 (1998) 3189-3202
11. Reya T., Duncan A.W., Ailles L., et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423 (2003) 409-414
12. Jue S.F., Bradley R.S., Rudnicki J.A., Varmus H.E., and Brown A.M. The mouse Wnt-1 gene can act via a paracrine mechanism in transformation of mammary epithelial cells. Mol Cell Biol 12 (1992) 321-328
13. Huguet E.L., McMahon J.A., McMahon A.P., Bicknell R., and Harris A.L. Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res 54 (1994) 2615-2621
14. Bodmer W.F., Bailey C.J., Bodmer J., et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 328 (1987) 614-616
15. Morin P.J., Sparks A.B., Korinek V., et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275 (1997) 1787-1790
16. Jin L.H., Shao Q.J., Luo W., Ye Z.Y., Li Q., and Lin S.C. Detection of point mutations of the Axin1 gene in colorectal cancers. Int J Cancer 107 (2003) 696-699
17. Dahmen R.P., Koch A., Denkhaus D., et al. Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res 61 (2001) 7039-7043
18. Clevers H. Axin and hepatocellular carcinomas. Nat Genet 24 (2000) 206-208
19. Marsit C.J., Karagas M.R., Andrew A., et al. Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res 65 (2005) 7081-7085
20. Bu X.M., Zhao C.H., Zhang N., et al. Hypermethylation and aberrant expression of secreted fizzled-related protein genes in pancreatic cancer. World J Gastroenterol 14 (2008) 3421-3424
21. Takagi H., Sasaki S., Suzuki H., et al. Frequent epigenetic inactivation of SFRP genes in hepatocellular carcinoma. J Gastroenterol 43 (2008) 378-389
22. Wong S.C., Lo S.F., Lee K.C., et al. Expression of frizzled-related protein and Wnt-signalling molecules in invasive human breast tumours. J Pathol 196 (2002) 145-153
23. Hoang B.H., Kubo T., Healey J.H., et al. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 109 1 (2004) 106-111
24. Hovanes K., Li T.W.H., Munguia J.E., et al. β-catenin-sensitive isoforms of lymphoid enhancer factor 1 are selectively expressed in colon cancer. Nat Genet 28 (2001) 5-57
25. Aoki M., Hecht A., Kruse U., Kemler R., and Vogt P.K. Nuclear endpoint of Wnt signaling: neoplastic transformation induced by transactivating lymphoid-enhancing factor 1. Proc Natl Acad Sci USA 96 (1999) 139-144
26. Khan N.I., Bradstock K.F., and Bendall L.J. Activation of Wnt/beta-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia. Br J Haematol 138 (2007) 338-348
27. Mazieres J., You L., He B., et al. Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis. Oncogene 24 (2005) 5396-5400
28. Roman-Gomez J., Jimenez-Velasco A., Agirre X., et al. Transcriptional silencing of the Dickkopfs-3 (Dkk-3) gene by CpG hypermethylation in acute lymphoblastic leukaemia. Br J Cancer 91 (2004) 707-713
29. Serinsoz E., Neusch M., Busche G., et al. Aberrant expression of beta-catenin discriminates acute myeloid leukaemia from acute lymphoblastic leukaemia. Br J Haematol 126 (2004) 313-319
30. Simon M., Grandage V.L., Linch D.C., and Khwaja A. Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia. Oncogene 24 (2005) 2410-2420
31. Muller-Tidow C., Steffen B., Cauvet T., et al. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol 24 (2004) 2890-2904
32. Luo H., Li Q., O'Neal J., et al. C-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood 106 (2005) 2452-2461
33. Lu D., Zhao Y., Tawatao R., et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 01 (2004) 3118-3123
34. Jelinek D.F., Tschumper R.C., Stolovitzky G.A., et al. Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Mol Cancer Res 1 (2003) 346-361
35. Liu T.H., Raval A., Chen S.S., et al. CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. Cancer Res 66 (2006) 653-658
36. Chim C.S., Fung T.K., Wong K.F., Lau J.S., and Liang R. Infrequent Wnt inhibitory factor-1 (Wif-1) methylation in chronic lymphocytic leukemia. Leuk Res 30 (2006) 1135-1139
37. Radich J.P., Dai H., Mao M., et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 103 (2006) 2794-2799
38. Jamieson C.H., Ailles L.E., Dylla S.J., et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. New Engl J Med 351 (2004) 657-667
39. Zhao C., Blum J., Chen A., et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 12 (2007) 528-541
40. Derksen P.W., Tjin E., Meijer H.P., et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci USA 101 (2004) 6122-6127
41. Kaiser M., Mieth M., Liebisch P., et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 80 (2008) 490-494
42. Dorfman D.M., Greisman H.A., and Shahsafaei A. Loss of expression of the WNT/beta-catenin-signaling pathway transcription factors lymphoid enhancer factor-1 (LEF-1) and T cell factor-1 (TCF-1) in a subset of peripheral T cell lymphomas. Am J Pathol 162 (2003) 1539-1544
43. Bellei B., Pacchiarotti A., Perez M., and Faraggiana T. Frequent beta-catenin overexpression without exon 3 mutation in cutaneous lymphomas. Mod Pathol 17 (2004) 1275-1281
44. Polanec J., Pavelic Z.P., and Myers W.L. Effect of Wnt-1 antisense RNA on the outgrowth of a mammary adenocarcinoma cell line expressing that oncogene. Clin Mol Pathol 49 (1996) M166-M169
45. He B., You L., Uematsu K., et al. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 6 (2004) 7-14
46. You L., He B., Xu Z., et al. An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res 64 (2004) 5385-5389
47. Nagayama S., Fukukawa C., Katagiri T., et al. Therapeutic potential of antibodies against FZD 10, a cell-surface protein, for synovial sarcomas. Oncogene 24 (2005) 6201-6212
48. Fukukawa C., Hanaoka H., Nagayama S., et al. Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. Cancer Sci 99 (2008) 432-440
49. Shih I.M., Yu J., He T.C., Vogelstein B., and Kinzler K.W. The beta-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression. Cancer Res 60 (2000) 1671-1676
50. Satoh S., Daigo Y., Furukawa Y., et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 24 (2000) 245-250
51. Roh H., Green D.W., Boswell C.B., Pippin J.A., and Drebin J.A. Suppression of beta-catenin inhibits the neoplastic growth of APC-mutant colon cancer cells. Cancer Res 61 (2001) 6563-6568
52. Veeramachaneni N.K., Kubokura H., Lin L., et al. Down-regulation of beta catenin inhibits the growth of esophageal carcinoma cells. J Thorac Cardiovasc Surg 127 (2004) 92-98
53. Verma U.N., Surabhi R.M., Schmaltieg A., Becerra C., and Gaynor R.B. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 9 (2003) 1291-1300
54. Chung E.J., Hwang S.G., Nguyen P., et al. Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. Blood 100 (2002) 982-990
55. Luu H.H., Zhang R., Haydon R.C., et al. Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets 4 (2004) 653-671
56. Lepourcelet M., Chen Y.N., France D.S., et al. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 5 (2004) 91-102
57. Iversen P.L., Arora V., Acker A.J., Mason D.H., and Devi G.R. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin Cancer Res 9 (2003) 2510-2519
58. Whittaker S.R., Walton M.I., Garrett M.D., and Workman P. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res 64 (2004) 262-272
59. Araki Y., Okamura S., Hussain S.P., et al. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 63 (2003) 728-734
60. Gardner S.H., Hawcroft G., and Hull M.A. Effect of nonsteroidal anti-inflammatory drugs on beta-catenin protein levels and catenin-related transcription in human colorectal cancer cells. Br J Cancer 91 (2004) 153-163
61. Rigas B., and Kashfi K. Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol Med 10 (2004) 324-330
62. Nath N., Kashfi K., Chen J., and Rigas B. Nitric oxide-donating aspirin inhibits beta-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin-TCF association. Proc Natl Acad Sci USA 100 (2003) 12584-12589
63. Robak P., Linke A., Cebula B., Robak T., and Smolewski P. Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells. Leuk Lymphoma 47 (2006) 2625-2634
64. Ross D.M., and Hughes T.P. Cancer treatment with kinase inhibitors: what have we learnt from imatinib?. Br J Cancer 90 (2004) 12-19
65. Zhou L., An N., Haydon R.C., et al. Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity. Cancer Lett 193 (2003) 161-170
66. Aloyz R., Grzywacz K., Xu Z.Y., et al. Imatinib sensitizes CLL lymphocytes to chlorambucil. Leukemia 18 (2004) 409-414